The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-py razol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-( 1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof； and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer. The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-p yrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-( 1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.La invención se relaciona con una combinación de un primer compuesto que se selecciona de N-3,5-dimetoxifenil)-N´-(1-metil-et il)-N-[3-(1-metil-1H-pirazol-4-il)quinoxalin-6-il]etano-1,2-diami na o una sal farmacéuticamente aceptable del mismo o un solvato del mismo, y N-(2-fluoro-3,5-dimetoxifenil)-N-(1H-imidazol-2-ilmet il)-3-(1-metil-1H-pirazol-4-il)pirido[2,3-b]pirazin-6-amina o una sal farmacéuticamente aceptable del mismo o un solvato del mismo； y un segundo compuesto el cual es un inhibidor de cMet. La combinación es para el uso en el tratamiento de un trastorno proliferativo, en particular para usarse en el tratamiento de cáncer. El inhibidor de FGFR (N- (3,5-dimetoxifenil)-N´-(1-metilet il)-N-[3-(1-metil-1H-pirazol-4-il)quinoxalin-6-il]et
